Pfizer (PFE)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
$24.07+1.48%
Close 2026-07-07 · 1-day change
Reading PFE? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track PFE free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
Reading PFE? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track PFE free→QuarterlyIQ Insights · PFE
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 11 valuation methods, at three horizons. Current price $24.07. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $24 PFE trades at 7.9× p/e, below its 25× p/e peer median. Our $32 fair value sits well above the price. We hold it with low confidence: our number sits above the analyst range and the peer anchor overstates how cheap it looks. Analysts target $26–$30. Note: our $32 fair value sits above the entire analyst range ($26–$30). Not investment advice.
$26.00 – $30.00 (median $27.00) · 5 analysts · as of 2026-07-06
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $2.07/sh owner earnings.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $27.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $8.78 | — | — | Hist. CAGR | high |
| graham number | 12M | $32.96 | — | — | TTM | high |
| Mgmt guidance | 12M | $72.97 | 25.2 | 2.90 | Mgmt | high |
| Peer EV/EBITDA | 12M | $19.82 | 9.3 | 3.29 | TTM | high |
| Peer P/FCF | 12M | $27.96 | 16.9 | 1.65 | TTM | high |
| Peer P/E | 12M | $77.00 | 25.2 | 3.06 | TTM | high |
| Peer P/S | 12M | $28.17 | 2.6 | 11.05 | TTM | high |
| residual income | 12M | $22.49 | — | — | TTM | high |
| Own P/E history | 12M | $28.19 | 9.2 | 3.06 | TTM | high |
| triangulated | 12M | $83.74 | 25.2 | 3.33 | Triangulated | high |
| Mgmt guidance | 3Y | $62.26 | 25.2 | 2.47 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $13.12 | 16.9 | 0.78 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $65.70 | 25.2 | 2.61 | Analyst | medium |
| Peer P/S | 3Y | $25.20 | 2.6 | 9.88 | guidance | medium |
| Own P/E history | 3Y | $24.05 | 9.2 | 2.61 | Analyst | medium |
| Mgmt guidance | 5Y | $56.01 | 25.2 | 2.23 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $7.93 | 16.9 | 0.47 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $59.10 | 25.2 | 2.35 | Analyst | high |
| Peer P/S | 5Y | $23.39 | 2.6 | 9.17 | guidance | high |
| Own P/E history | 5Y | $21.63 | 9.2 | 2.35 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.